Global Information
회사소개 | 문의 | 비교리스트

고인슐린혈증 : 파이프라인 리뷰

Hyperinsulinemia (Metabolic Disorder) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 410991
페이지 정보 영문 85 Pages 배송안내
가격
US $ 2,000 ₩ 2,543,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,086,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,630,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


고인슐린혈증 : 파이프라인 리뷰 Hyperinsulinemia (Metabolic Disorder) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 85 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

고인슐린혈증은 혈액중 포도당치에 대해 혈중 과잉 인슐린이 순환하고 있는 상태를 가리킵니다. 인슐린 내성이 고인슐린혈증의 근본적인 원인입니다. 증상은 체중 증가, 불안감, 피로, 거듭되는 공복감 등입니다. 위험인자로 높은 트리그리세리드치, 고요산, 체중 증가, 2형 당뇨병, 고혈압 등을 들 수 있습니다. 치료에는 인슐린 분비 저해제의 이용, 다이어트, 운동, 기타 생활 스타일의 변경 등이 있습니다.

고인슐린혈증 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

고인슐린혈증 개요

치료제 개발

  • 파이프라인 제품;개요
  • 파이프라인 제품;비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품의 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • Eiger BioPharmaceuticals Inc
  • Heptares Therapeutics Ltd
  • Seneb BioSciences Inc
  • XOMA Corp

치료제 평가

  • 단일요법 제품
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

  • exendin-(9-39)
  • 저혈당증·선천성 고인슐린혈증용 GLP-1 수용체 길항제
  • SNB-2401
  • XOMA-358

휴지중인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSA 17.02.15

List of Tables

List of Tables

  • Number of Products under Development for Hyperinsulinemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hyperinsulinemia - Pipeline by AmideBio LLC, 2021
  • Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, 2021
  • Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, 2021
  • Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
  • Hyperinsulinemia - Pipeline by PegBio Co Ltd, 2021
  • Hyperinsulinemia - Pipeline by Rezolute Inc, 2021
  • Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, 2021
  • Hyperinsulinemia - Pipeline by XERIS Pharmaceuticals Inc, 2021
  • Hyperinsulinemia - Pipeline by Zealand Pharma AS, 2021
  • Hyperinsulinemia - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hyperinsulinemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Drugs In Development, 2021, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecule, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hyperinsulinemia - Overview
  • Hyperinsulinemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hyperinsulinemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hyperinsulinemia - Companies Involved in Therapeutics Development
  • AmideBio LLC
  • Crinetics Pharmaceuticals Inc
  • Eiger BioPharmaceuticals Inc
  • Hanmi Pharmaceuticals Co Ltd
  • PegBio Co Ltd
  • Rezolute Inc
  • Seneb BioSciences Inc
  • XERIS Pharmaceuticals Inc
  • Zealand Pharma AS
  • Hyperinsulinemia - Drug Profiles
  • Hyperinsulinemia - Dormant Projects
  • Hyperinsulinemia - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q